-
Product Insights
NewPolyarticular Juvenile Idiopathic Arthritis (PJIA) – Drugs In Development, 2024
Empower your strategies with our Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Drugs In Development, 2024 report and make more profitable business decisions. Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in the small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling, and problems with bone development and growth. Treatment includes painkillers, non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying...
-
Product Insights
NewSystemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2024
Empower your strategies with our Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Systemic-onset juvenile idiopathic arthritis (Still's disease) is a rare and serious form of arthritis that affects children. It causes inflammation not only in the joints, but also in other organs such as the liver, heart, and lungs. It is also known as systemic juvenile rheumatoid arthritis or juvenile-onset Still's disease. The main symptoms of this condition are high...
-
Product Insights
NewChemotherapy Induced Neutropenia – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Neutropenia – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain, dizziness, and abdominal pain. The predisposing factors include age, co-morbidities, and time course of therapy. The Chemotherapy Induced Neutropenia drugs in development market research report provide comprehensive information...
-
Product Insights
NewJuvenile Arthritis – Drugs In Development, 2024
Empower your strategies with our Juvenile Arthritis – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile arthritis (JA), also known as pediatric rheumatic disease, encompasses a group of inflammatory conditions affecting children and adolescents under the age of 16. This condition causes chronic joint inflammation, leading to stiffness, pain, swelling, and potential damage to joints and other tissues. Diagnosis of juvenile arthritis involves a comprehensive evaluation by a pediatric rheumatologist. It includes a physical examination, assessment of...
-
Product Insights
NewPsoriatic Arthritis – Drugs In Development, 2024
Empower your strategies with our Psoriatic Arthritis – Drugs In Development, 2024 report and make more profitable business decisions. Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain, and lower back pain. Risk factors include age, family history, and psoriasis. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and surgery. The Psoriatic Arthritis drugs in development market research report provide comprehensive information on the therapeutics under development for Psoriatic...
-
Product Insights
NewLeukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024
Empower your strategies with our Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024 report and make more profitable business decisions. Leukocyte disorders, also known as white blood cell disorders, encompass a range of conditions that involve abnormalities in the production, function, or levels of white blood cells (leukocytes). White blood cells play a crucial role in the immune system, defending the body against infections, diseases, and foreign invaders. The Leukocyte Disorders (White Blood Cell Disorders) drugs in development...
-
Product Insights
NewAxial Spondyloarthritis – Drugs In Development, 2024
Empower your strategies with our Axial Spondyloarthritis – Drugs In Development, 2024 report and make more profitable business decisions. Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available. The Axial Spondyloarthritis drugs in development market research report provide comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target,...
-
Product Insights
NewAnkylosing Spondylitis (Bekhterev’s Disease) – Drugs In Development, 2024
Empower your strategies with our Ankylosing Spondylitis (Bekhterev's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture. The Ankylosing Spondylitis (Bekhterev's Disease) drugs...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...